Korsana Biosciences KRSA
NASDAQ KRSA
$30.49 -0.71 (-2.28%)
At close: Oct 2, 2026 · 4:00 PM EDT

Korsana Biosciences (KRSA) Gains from Sales and Divestitures (2019 - 2021)

Updated

Korsana Biosciences' Gains from Sales and Divestitures was -$6.32 million in FY2021, compared with $159,000 in FY2020.

Analysis

Korsana Biosciences (KRSA) Gains from Sales and Divestitures (2019 - 2021) Analysis & Trends

  • Per Business Quant data, Gains from Sales and Divestitures in earlier years was $159,000 in FY2020 and -$751,000 in FY2019.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Korsana Biosciences 16.10 Mn 1.64 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 -6.33 Mn
Mar 31, 2021 12,000.00
Dec 31, 2020 364,000.00
Sep 30, 2020 -11,000.00
Jun 30, 2020 -235,000.00
Mar 31, 2020 41,000.00
Dec 31, 2019 -675,000.00
API Access

Korsana Biosciences Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=KRSA&period=max&api_key=YOUR_API_KEY